AXIONOVA Research Disclaimer

1. Core Research Use Only Statement

AXIONOVA is a precision bio-science and longevity platform organized around 30 verified compounds across 10 biological systems, governed access, practitioner review, compound identity records, chain-of-custody controls, device-event context, physiology trends, and AI-assisted support. Unless AXIONOVA expressly states otherwise in a signed, product-specific, jurisdiction-specific written authorization, AXIONOVA compounds, compound documentation, protocol structures, stack descriptions, biological-system logic, and related catalog materials are provided for Research Use Only (RUO).

Where applicable as a U.S. RUO labeling benchmark, FDA regulations for in vitro diagnostic products recognize the statement “For Research Use Only. Not for use in diagnostic procedures.” in 21 CFR 809.10(c)(2)(i). AXIONOVA cites this language as a RUO boundary reference where relevant; it does not classify every AXIONOVA material as an in vitro diagnostic product. Final classification must be confirmed by qualified regulatory counsel and applicable authorities.

2. No FDA Approval, No COFEPRIS Authorization for Therapeutic Use Unless Expressly Stated

AXIONOVA materials should not be interpreted as evidence that any compound, stack, protocol, device, AI output, wellness trend, or practitioner-support material has been reviewed, cleared, approved, registered, or authorized by the U.S. Food and Drug Administration (FDA), Mexico’s Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), or any other health authority for treatment, diagnosis, cure, mitigation, prevention, human consumption, human injection, disease management, or public therapeutic marketing.

COFEPRIS is Mexico’s sanitary-risk authority for health inputs, health establishments, sanitary permits, sanitary registrations, licenses, import, and related proceedings. Any use, import, export, distribution, research, storage, handling, labeling, advertising, or professional activity involving AXIONOVA materials in Mexico must be evaluated under applicable COFEPRIS, Ley General de Salud, Reglamento de Insumos para la Salud, consumer-protection, customs, and professional requirements.

3. No Medical Advice, Diagnosis, Treatment, or Emergency Service

AXIONOVA website content, access-gate materials, catalog entries, biological-system descriptions, compound summaries, certificate references, protocol windows, stack structures, SENSE trends, AXIS events, AXIONOVA bio records, ALETHA outputs, ALETHRA audit records, practitioner-support materials, and reseller-support materials are for informational, research, governance, education, compliance, and recordkeeping purposes only.

AXIONOVA does not provide medical advice, diagnosis, treatment, prescription, dispensing instruction, emergency care, or individualized therapeutic direction through public materials or AI-assisted outputs. Any individual experiencing symptoms, adverse events, or a potential emergency should contact emergency services or a licensed medical professional immediately.

HALO Research and Validation Boundary

HALO public materials may describe dual-device verification, preventative monitoring, baseline-aware optimization, signal-confidence review, provenance, consent controls, and approved workflow boundaries. HALO materials must not describe HALO as a standalone emergency system, diagnostic system, automated medical decision-maker, or substitute for emergency services. Emergency Response may be referenced only as an exclusive HALO capability available through approved configuration, validation, jurisdictional review, and governed access.

4. Practitioner and Research-Entity Responsibility

AXIONOVA access is governed through two paths. Path 1 is for licensed practitioners and qualified organizations that submit credentials and documentation. Path 2 is for trainers, spas, coaches, and individuals who require AXIONOVA’s on-staff doctors for telehealth oversight. Both paths remain subject to RUO boundaries, consent requirements, documentation, privacy review, jurisdictional availability, and human oversight. These parties remain independently responsible for evaluating whether any activity involving AXIONOVA materials is lawful, ethical, properly approved, properly supervised, appropriately documented, and consistent with their own professional duties.

AXIONOVA’s provision of information, access review, certificates, AI support, or governance tools does not replace the user’s duty to obtain independent legal, regulatory, clinical, scientific, and ethics review.

5. Governed Access Gate and Eligibility

AXIONOVA uses a governed access gate to confirm basic eligibility and acknowledgements before restricted materials are released. Access-gate acceptance does not guarantee approval, product availability, purchase rights, regulatory authorization, clinical eligibility, reseller authorization, import/export permission, or permission to use materials outside RUO boundaries.

AXIONOVA may monitor and log access-gate activity, restricted catalog access, Datasite room access, DocuSign attestations, AXIONOVA bio access, ALETHRA governance records, AXIS events, SENSE integrations, and partner portal activity. AXIONOVA may deny, revoke, suspend, or condition access where it identifies suspected misuse, diversion risk, unsupported claims, security concerns, credential issues, jurisdictional restrictions, or inconsistent intended use.

6. ALETHRA Governance Is Not Proof of Therapeutic Effect

ALETHRA is AXIONOVA’s governance layer for identity, verification, authorization, chain-of-custody, access controls, compliance records, cartridge records, device-event logs, and provenance. ALETHRA certification or verification may support identity review, lot traceability, document control, access authorization, audit readiness, and record integrity.

ALETHRA certification does not mean that a compound is FDA-approved, COFEPRIS-authorized for therapeutic use, clinically proven for a disease claim, safe for human use, effective for any outcome, or appropriate for a particular person. A verified source record is not a clinical conclusion.

7. ALETHA AI Is Supportive, Not Determinative

ALETHA is AXIONOVA’s AI operator for guided education, coaching, diet programming, protocol-context explanation, progress review, user support, and practitioner-review preparation. ALETHA may process source data, AXIS events, SENSE trends, laboratory data, symptoms, adherence, nutrition, notes, and practitioner inputs to generate summaries, suggestions, explanations, or review flags.

ALETHA outputs are not medical advice, not diagnoses, not prescriptions, not emergency instructions, not proof of compound effect, not regulatory determinations, and not substitutes for licensed practitioner judgment. AI outputs may be incomplete, inaccurate, biased, stale, or unsuitable for a specific user, population, research design, jurisdiction, or professional standard. Protocol-dependent decisions must be routed through authorized professional review.

8. AXIONOVA bio: Data Levels and Interpretation Boundaries

AXIONOVA bio is designed to distinguish source data, derived wellness features, protocol context, and review logic. AXIONOVA’s public materials emphasize that a PPG waveform is not HRV by itself, HRV is not a diagnosis, a BioZ trend is not a body-composition replacement, and a protocol window is not proof of compound effect.

Users must not remove or contradict AXIONOVA boundary labels, confidence labels, investigational labels, validation-roadmap labels, or practitioner-review requirements.

9. AXIS and SENSE Boundaries

AXIS is described as a governed delivery instrument that preserves manual user action while recording identity, lock-state confirmation, authorization, protocol-compliance context, and event traceability. SENSE is described as a dual wearable physiology system that streams trends such as heart rate, HRV, sleep context, temperature deviation, activity context, SpO₂ research-trend support, EDA, and BioZ context into AXIONOVA bio.

AXIS and SENSE outputs must be interpreted according to validated use, applicable labeling, signal quality, user context, and jurisdictional regulatory status. Unless expressly authorized in writing, AXIS, SENSE, and related outputs are not represented as devices or outputs approved to diagnose, treat, cure, mitigate, or prevent disease. AXIS event records do not prove correct use, safety, efficacy, sterility, suitability, or therapeutic outcome.

10. Protocols, Stacks, and Biological Systems

AXIONOVA protocol structures, stack logic, and biological-system classifications are designed to organize research objectives, pathway context, timing, monitoring requirements, companion-compound logic, and documentation workflows. A stack is a protocol structure, not a consumer product bundle, prescription, dosing instruction, or guaranteed outcome.

Any descriptions of weight loss, repair, recovery, regenerative, longevity, performance, cognitive, hormonal, metabolic, immune, or other biological systems are research-context descriptions. They must not be converted into consumer therapeutic claims, disease claims, guaranteed benefit claims, or instructions for human use unless supported by applicable regulatory authorization and written AXIONOVA approval.

11. Advertising, Marketing, and Public Statements

All advertising, promotional, educational, reseller, practitioner, conference, social media, email, website, and investor-facing statements about AXIONOVA must be truthful, non-misleading, appropriately substantiated, and consistent with AXIONOVA-approved materials. FTC health-products guidance requires health-related claims to be truthful, not misleading, and supported by adequate substantiation, generally competent and reliable scientific evidence.

Mexico’s Federal Consumer Protection Law requires information and advertising to be truthful, verifiable, clear, and free from misleading or abusive content, and imposes specific obligations for electronic transactions, including confidentiality, security, truthful product characteristics, clear terms, and honoring consumer advertising preferences.

No AXIONOVA user, reseller, practitioner, clinic, research entity, partner, employee, contractor, or affiliate may make unauthorized statements that AXIONOVA materials are FDA-approved, COFEPRIS-authorized for therapeutic use, clinically proven for disease treatment, safe for unsupervised human use, guaranteed to produce results, endorsed by AXIONOVA for consumer therapeutic use, or suitable for a particular person.

12. No Reliance on Public Website Content

AXIONOVA public website content is intended to describe AXIONOVA’s platform, access model, governance architecture, research-use taxonomy, technology roadmap, and professional workflows. Public content may be updated, incomplete, delayed, aspirational, jurisdiction-limited, or subject to regulatory validation. It should not be relied upon as final labeling, final regulatory classification, professional instructions, research protocol approval, import/export authorization, investment advice, medical advice, or legal advice.

Restricted materials may be subject to separate agreements, non-disclosure obligations, data-room controls, DocuSign acknowledgements, jurisdictional limits, reseller restrictions, and professional review requirements.

13. International and Mexico-Specific Notice

AXIONOVA’s international access currently includes U.S. and Mexico-oriented workflows, with other jurisdictions potentially added later. Users outside the United States must not assume that a U.S.-oriented RUO statement permits possession, import, export, research, distribution, advertising, professional use, human use, or resale in their jurisdiction.

In Mexico, activities involving health inputs, research materials, importation, sanitary control, advertising, professional conduct, and electronic commerce may be regulated by COFEPRIS, Ley General de Salud, Reglamento de Insumos para la Salud, Ley Federal de Protección al Consumidor, LFPDPPP, customs rules, tax rules, and professional requirements. Mexico-facing materials may require Spanish labeling, Spanish notices, local responsible-party information, transfer disclosures, and legally compliant privacy notices.

14. Adverse Events, Safety Signals, and Reporting

AXIONOVA does not invite or authorize unauthorized human use of RUO materials. If AXIONOVA receives information suggesting an adverse event, misuse, diversion, unauthorized human use, improper claim, product quality concern, device issue, privacy incident, security incident, or regulatory concern, AXIONOVA may preserve records, suspend access, request documentation, notify appropriate parties, and take corrective or preventive action as required or appropriate.

Users, practitioners, clinics, resellers, and research entities must promptly report suspected misuse, diversion, product-quality issues, device anomalies, labeling concerns, unauthorized claims, access breaches, and safety signals to AXIONOVA at safety@axionova.com or legal@axionova.com. Reporting a concern to AXIONOVA does not replace any legally required report to regulators, institutional review boards, ethics committees, professional boards, emergency services, or other authorities.

15. Required Placement and Repetition of Disclaimer

AXIONOVA should place a concise version of this disclaimer in high-risk contexts, including the access gate, catalog pages, compound pages, protocol pages, stack pages, AXIS/SENSE pages, AXIONOVA bio onboarding, ALETHA sessions, DocuSign acknowledgements, Datasite rooms, reseller documents, clinic onboarding, certificates, lot records, labels, inserts, marketing approvals, and email communications.

A short-form disclaimer may read:

16. Contact

Questions regarding this Research Disclaimer, suspected misuse, unsupported claims, jurisdictional restrictions, product-quality issues, AI-output concerns, safety signals, or regulatory issues may be sent to: